Search results
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
With Christmas parties upon us, come and join Bhavini as she shares her top tips for selecting the right make up, The best way to apply and blend, how to shop for makeup and picking the right colours.
Volunteers founded our charity in the 1970s and they continue to be at our heart.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.
